collection
MENU ▼
Read by QxMD icon Read
search

Internal Medicine Essentials

shared collection
10 papers 0 to 25 followers Guidelines and landmark articles
By Dimas Yusuf Canadian-trained medical doctor and internal medicine resident with a passion for medical informatics
https://www.readbyqxmd.com/read/27036919/duration-of-dual-antiplatelet-therapy-a-systematic-review-for-the-2016-acc-aha-guideline-focused-update-on-duration-of-dual-antiplatelet-therapy-in-patients-with-coronary%C3%A2-artery-disease-a-report-of-the-american-college-of-cardiology-american-heart-association
#1
John A Bittl, Usman Baber, Steven M Bradley, Duminda N Wijeysundera
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after implantation of newer-generation drug-eluting stents (DES) remains uncertain. Similarly, questions remain about the role of DAPT in long-term therapy of stable post-myocardial infarction (MI) patients. AIM: Our objective was to compare the incidence of death, major hemorrhage, MI, stent thrombosis, and major adverse cardiac events in patients randomized to prolonged or short-course DAPT after implantation of newer-generation DES and in secondary prevention after MI...
September 6, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/26928912/diagnosis-and-management-of-diabetes-synopsis-of-the-2016-american-diabetes-association-standards-of-medical-care-in-diabetes
#2
James J Chamberlain, Andrew S Rhinehart, Charles F Shaefer, Annie Neuman
DESCRIPTION: The American Diabetes Association (ADA) published the 2016 Standards of Medical Care in Diabetes (Standards) to provide clinicians, patients, researchers, payers, and other interested parties with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. METHODS: The ADA Professional Practice Committee performed a systematic search on MEDLINE to revise or clarify recommendations based on new evidence. The committee assigns the recommendations a rating of A, B, or C, depending on the quality of evidence...
April 19, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/26867832/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report
#3
Clive Kearon, Elie A Akl, Joseph Ornelas, Allen Blaivas, David Jimenez, Henri Bounameaux, Menno Huisman, Christopher S King, Timothy A Morris, Namita Sood, Scott M Stevens, Janine R E Vintch, Philip Wells, Scott C Woller, Lisa Moores
BACKGROUND: We update recommendations on 12 topics that were in the 9th edition of these guidelines, and address 3 new topics. METHODS: We generate strong (Grade 1) and weak (Grade 2) recommendations based on high- (Grade A), moderate- (Grade B), and low- (Grade C) quality evidence. RESULTS: For VTE and no cancer, as long-term anticoagulant therapy, we suggest dabigatran (Grade 2B), rivaroxaban (Grade 2B), apixaban (Grade 2B), or edoxaban (Grade 2B) over vitamin K antagonist (VKA) therapy, and suggest VKA therapy over low-molecular-weight heparin (LMWH; Grade 2C)...
February 2016: Chest
https://www.readbyqxmd.com/read/26551272/a-randomized-trial-of-intensive-versus-standard-blood-pressure-control
#4
RANDOMIZED CONTROLLED TRIAL
Jackson T Wright, Jeff D Williamson, Paul K Whelton, Joni K Snyder, Kaycee M Sink, Michael V Rocco, David M Reboussin, Mahboob Rahman, Suzanne Oparil, Cora E Lewis, Paul L Kimmel, Karen C Johnson, David C Goff, Lawrence J Fine, Jeffrey A Cutler, William C Cushman, Alfred K Cheung, Walter T Ambrosius
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes...
November 26, 2015: New England Journal of Medicine
https://www.readbyqxmd.com/read/26546661/management-of-chronic-hepatitis-b-an-overview-of-practice-guidelines-for-primary-care-providers
#5
REVIEW
Steven-Huy Han, Tram T Tran
Despite the introduction of hepatitis B virus (HBV) vaccination programs, chronic hepatitis B (CHB) remains an important disease burden worldwide and in the United States. A number of clinical practice guidelines are available to assist in the clinical management of CHB by providing recommendations regarding screening and diagnosis, treatment indications, and the choice, duration, and monitoring of treatment. Adherence to these guidelines has proven beneficial in terms of better treatment compliance, improved clinical outcomes, and lower likelihoods of emergency admission...
November 2015: Journal of the American Board of Family Medicine: JABFM
https://www.readbyqxmd.com/read/26545940/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis
#6
REVIEW
Jasvinder A Singh, Kenneth G Saag, S Louis Bridges, Elie A Akl, Raveendhara R Bannuru, Matthew C Sullivan, Elizaveta Vaysbrot, Christine McNaughton, Mikala Osani, Robert H Shmerling, Jeffrey R Curtis, Daniel E Furst, Deborah Parks, Arthur Kavanaugh, James O'Dell, Charles King, Amye Leong, Eric L Matteson, John T Schousboe, Barbara Drevlow, Seth Ginsberg, James Grober, E William St Clair, Elizabeth Tindall, Amy S Miller, Timothy McAlindon
OBJECTIVE: To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). METHODS: We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional)...
January 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26399663/2015-acc-aha-hrs-guideline-for-the-management-of-adult-patients-with-supraventricular-tachycardia-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice-guidelines-and-the-heart-rhythm-society
#7
Richard L Page, José A Joglar, Mary A Caldwell, Hugh Calkins, Jamie B Conti, Barbara J Deal, N A Mark Estes, Michael E Field, Zachary D Goldberger, Stephen C Hammill, Julia H Indik, Bruce D Lindsay, Brian Olshansky, Andrea M Russo, Win-Kuang Shen, Cynthia M Tracy, Sana M Al-Khatib
No abstract text is available yet for this article.
April 5, 2016: Circulation
https://www.readbyqxmd.com/read/26111063/hepatitis-c-guidance-aasld-idsa-recommendations-for-testing-managing-and-treating-adults-infected-with-hepatitis-c-virus
#8
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
September 2015: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/26095867/perioperative-bridging-anticoagulation-in-patients-with-atrial-fibrillation
#9
RANDOMIZED CONTROLLED TRIAL
James D Douketis, Alex C Spyropoulos, Scott Kaatz, Richard C Becker, Joseph A Caprini, Andrew S Dunn, David A Garcia, Alan Jacobson, Amir K Jaffer, David F Kong, Sam Schulman, Alexander G G Turpie, Vic Hasselblad, Thomas L Ortel
BACKGROUND: It is uncertain whether bridging anticoagulation is necessary for patients with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or other elective invasive procedure. We hypothesized that forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight heparin for the prevention of perioperative arterial thromboembolism and would be superior to bridging with respect to major bleeding. METHODS: We performed a randomized, double-blind, placebo-controlled trial in which, after perioperative interruption of warfarin therapy, patients were randomly assigned to receive bridging anticoagulation therapy with low-molecular-weight heparin (100 IU of dalteparin per kilogram of body weight) or matching placebo administered subcutaneously twice daily, from 3 days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure...
August 27, 2015: New England Journal of Medicine
https://www.readbyqxmd.com/read/26095467/screening-for-occult-cancer-in-unprovoked-venous-thromboembolism
#10
RANDOMIZED CONTROLLED TRIAL
Marc Carrier, Alejandro Lazo-Langner, Sudeep Shivakumar, Vicky Tagalakis, Ryan Zarychanski, Susan Solymoss, Nathalie Routhier, James Douketis, Kim Danovitch, Agnes Y Lee, Gregoire Le Gal, Philip S Wells, Daniel J Corsi, Timothy Ramsay, Doug Coyle, Isabelle Chagnon, Zahra Kassam, Hardy Tao, Marc A Rodger
BACKGROUND: Venous thromboembolism may be the earliest sign of cancer. Currently, there is a great diversity in practices regarding screening for occult cancer in a person who has an unprovoked venous thromboembolism. We sought to assess the efficacy of a screening strategy for occult cancer that included comprehensive computed tomography (CT) of the abdomen and pelvis in patients who had a first unprovoked venous thromboembolism. METHODS: We conducted a multicenter, open-label, randomized, controlled trial in Canada...
August 20, 2015: New England Journal of Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"